Top Markets
#1 0G 0G +45.73%
#2 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#3 Useless Coin Useless Coin +30.72%
#4 SAFEcoin SAFEcoin +28.84%
#5 Dogs Dogs +24.05%
#6 Pons Pons +24.05%
#7 StonkBroker StonkBroker +21.73%
#8 ICON ICON +20.45%
#9 Zora Zora +20.32%
#10 Dash Dash +17.58%
Coin of the day
0G 0G
Settings
Language
ENGLISH
Currency
USD
Theme
Albireo Pharma, Inc. Albireo Pharma, Inc.

Albireo Pharma, Inc.

ALBO
Rank in Stocks #12829
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products,... Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
Share Price
$44.15
Last synced: 2023-03-02
Market Cap
$545.52M
Change (1 day)
-0.23%
Change (1 year)
0.00%
Country
US
Trade Albireo Pharma, Inc. (ALBO)

Category

Healthcare
P/E ratio for Albireo Pharma, Inc. (ALBO)
P/E ratio as of 2026 TTM: 0
According to Albireo Pharma, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Albireo Pharma, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.